The partnership was announced on 16 March 2015. With all regulatory approvals now received, DSM and CVC have completed the transaction. Approximately 1,900 employees have transferred to ChemicaInvest, which is 65% owned by CVC and 35% by DSM.

Transaction

DSM contributed its global caprolactam business (Europe, North America, its 60% stake in DNCC (China) and the caprolactam licensing business), acrylonitrile business and composite resins business including its 75% stake in JDR (China).

DSM's 65% stake in the service organization Sitech Services held via its caprolactam and acrylonitrile businesses was also transferred. ChemicaInvest operates as an independent company with three business units: caprolactam, acrylonitrile and composite resins.

Strategy

For DSM, this proposed transaction is a logical step in the execution of its strategy as polymer intermediates (caprolactam, acrylonitrile) and composite resins no longer fit with its more resilient portfolio in nutrition and performance materials.

The partnership with CVC allows DSM to further reduce the cyclicality of its portfolio, secure a long-term competitive supply position of caprolactam for DSM Engineering Plastics and fully focus on the nutrition, performance materials and innovation activities complemented by accelerated actions to improve efficiencies and reduce costs.

DSM

Royal DSM is a science based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences, DSM delivers innovative solutions that nourish, protect and improve performance in global markets.

The company’s products are used in food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.

www.dsm.com

DSM and CVC form new company for polymer intermediates and composite resins